Initiator Pharma

6.5

SEK

-1.52 %

Less than 1K followers

INIT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

-1.52%

-9.09%

-5.11%

-5.11%

-12.16%

-28.57%

-20.15%

+35.21%

+44.9%

Initiator Pharma is a biotechnology company. Today, the main focus is to develop drug candidates to be used in treatment of erectile dysfunction in men. The company currently has pharmaceuticals in clinical stage testing for patients that do not respond on PDE5i pharmaceuticals. Initiator Pharma was created as a spin-off from Saniona and is today based in Åbyhøj.

Market cap

365.03M SEK

Turnover

303.08K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Financial calendar

9.5

2025

Interim report Q1'25

23.5

2025

General meeting '25

22.8

2025

Interim report Q2'25

All

Press releases

ShowingAll content types

Regulatory press release3/25/2025, 7:30 AM

Dr. Göran Ando is proposed for election to Initiator Pharma’s Board of Directors and appointed as senior advisor in business development

Initiator Pharma

Press release3/14/2025, 12:29 PM

Carnegie Access: Initiator Pharma: Highlights from Carnegie’s Healthcare Conference

Initiator Pharma

Press release3/5/2025, 9:52 AM

Carnegie Access: Initiator Pharma: Partner collaboration is at the top of the agenda – Q4(24) review

Initiator Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release2/28/2025, 4:36 PM

Redeye: Initiator Pharma Q4 - Awaiting a licensing deal

Initiator Pharma

Regulatory press release2/28/2025, 7:30 AM

INITIATOR PHARMA: YEAR END REPORT 2024

Initiator Pharma

Press release11/29/2024, 12:27 PM

Redeye: Initiator Pharma Q3 - Continued efforts in business development

Initiator Pharma

Regulatory press release11/29/2024, 7:30 AM

INITIATOR PHARMA: Q3 2024 REPORT

Initiator Pharma

Regulatory press release11/4/2024, 4:20 PM

Completion of capital increase in Initiator Pharma

Initiator Pharma

Press release11/4/2024, 10:00 AM

Initiator Pharma will present at the BioStock Life Science Summit, November 20

Initiator Pharma

Regulatory press release10/25/2024, 6:30 AM

Finalization of share buyback program in Initiator Pharma

Initiator Pharma

Regulatory press release10/14/2024, 4:15 PM

Decision to issue new shares and conduct share buyback, as well as the sale of shares in connection with the long-term incentive program for 2023

Initiator Pharma

Press release8/23/2024, 10:08 AM

Redeye: Initiator Pharma Q2 - Silent advancements

Initiator Pharma

Regulatory press release8/23/2024, 6:30 AM

INITIATOR PHARMA: Q2 2024 REPORT

Initiator Pharma

Press release7/18/2024, 6:30 AM

Initiator Pharma’s international patent application regarding pudafensine's dosage regime for the treatment of erectile dysfunction has been published

Initiator Pharma

Regulatory press release5/24/2024, 8:45 AM

Initiator Pharma A/S - Resolutions of the annual general meeting 2024

Initiator Pharma

Press release5/10/2024, 10:30 AM

Redeye: Initiator Pharma Q1 2024 - Focus on sealing a deal

Initiator Pharma

Regulatory press release5/10/2024, 6:30 AM

INITIATOR PHARMA: Q1 2024 REPORT

Initiator Pharma

Regulatory press release5/2/2024, 6:45 AM

Notice to AGM in Initiator Pharma

Initiator Pharma

Regulatory press release5/2/2024, 6:30 AM

Annual report and Remuneration report 2023 for Initiator Pharma A/S

Initiator Pharma

Press release4/12/2024, 6:55 AM

Initiator Pharma’s pudafensine preclinical pharmacology results published in the British Journal of Pharmacology

Initiator Pharma

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.